LUCD at a glance
Lucid Diagnostics Inc. (LUCD, SEC CIK 1799011) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as February 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Lucid Diagnostics Inc. (LUCD) reported revenue of $4.7 million (up 8.3% from FY2024) and a net loss of $58.0 million. Diluted EPS was -$0.69.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Lucid Diagnostics Inc. (LUCD) shares worth $18.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.7M
- +8.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $18.1M · −1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $1.2M, flat versus $1.2M in Q3 2025
- Gross margin negative 16.7% versus negative 41.7% YoY, based on revenue and cost of revenue
- Sales and marketing worst-performing expense line: $5.3M, up from $4.3M YoY
- Cash $18.0M at September 30, 2026; operating cash use $38.9M for nine months
- Series C preferred offering generated $15.0M gross proceeds; going-concern doubt and recurring losses remain near-term headwinds
AI summary of the LUCD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Lucid Diagnostics announced fiscal quarter results for the period ended September 30, 2026
- Business update included alongside the quarterly financial release
Item EX-99.1: Item EX-99.1
- Nationwide Medicare reimbursement at $1,938.01 per EsoGuard test removes a major commercialization barrier
- Record October volume exceeded 1,800 tests after 2,871 tests in 3Q26, signaling early acceleration but requiring revenue conversion
Item 3.02: Unregistered Sales of Equity Securities
- $15.0M gross proceeds from 15,000 Series C preferred shares, strengthening liquidity through accredited-investor financing
- Initial conversion price $0.3519, creating substantial potential common-stock dilution subject to 4.99% holder and 19.99% Nasdaq limits
Item 3.03: Material Modification to Rights of Security Holders
- Security-holder rights modification links to Item 3.02 and Item 5.03 disclosures
- Investor impact depends on the financing terms and charter or bylaw changes described in those referenced sections
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Series C Certificate of Designation amended Lucid Diagnostics’ Delaware certificate of incorporation
- Amendment creates or governs Series C preferred stock rights, as detailed under Item 3.02
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq deficiency: LUCD closing bid below $1 for 30 consecutive business days through October 9, 2026
- Compliance deadline April 12, 2027, requiring a $1 bid price for 10 consecutive business days
AI summaries of LUCD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LUCD
Don't miss the next LUCD filing
- Alerts as it files. A push when LUCD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LUCD, by share count.
- Ask anything. An AI agent that reads every LUCD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MCGRATH DENNIS M | A | Feb 20, 2026 | 470,000 | - |
| Cox James L | A | Feb 20, 2026 | 123,000 | - |
| PALUMBO JOHN R | A | Feb 20, 2026 | 123,000 | - |
| White Debra | A | Feb 20, 2026 | 123,000 | - |
| Sparks Ronald M | A | Feb 20, 2026 | 123,000 | - |
| O'Neil Shaun | A | Feb 20, 2026 | 620,000 | - |
| SOKOLOV JACQUE J | A | Feb 20, 2026 | 123,000 | - |
| Aklog Lishan | A | Feb 20, 2026 | 2,170,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.3M | $4.7M |
| Operating Income | -$48.5M | -$46.1M | -$49.6M |
| Net Income | -$52.7M | -$45.5M | -$58.0M |
| Op. Margin | - | -1059.6% | -1054.8% |
| Net Margin | - | -1047.6% | -1232.7% |
| Balance Sheet | |||
| Total Assets | $27.3M | $30.7M | $40.4M |
| Equity | - | $5.4M | $10.9M |
| ROE | - | -844.5% | -530.4% |
| Per Share | |||
| EPS | $-1.26 | $-1.05 | $-0.69 |
| Cash Flow | |||
| Operating CF | - | -$44.1M | -$46.5M |
| CapEx | - | $296K | $197K |
Source: XBRL data in Lucid Diagnostics Inc. (LUCD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LUCD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $18.1M |
| Q2 2026 | 22 | $25.7M |
| Q1 2026 | 22 | $17.2M |
| Q4 2025 | 19 | $15.4M |
| Q3 2025 | 16 | $12.0M |
| Q2 2025 | 16 | $12.0M |
| Q1 2025 | 12 | $3.0M |
| Q4 2024 | 5 | $592,000 |
- Citadel Advisors LLC+608.2K (+1673%)
- Wells Fargo & Co+468.9K (+23%)
- Morgan Stanley+76.4K (+116%)
- Bank of America Corp+65.7K (+68%)
- Vanguard Portfolio Management LLC+44.3K (+4%)
- AQR Capital Management−603.7K (-83%)
- Vanguard Capital Management LLC−511.1K (-8%)
- Citigroup−62.1K (-89%)
- Goldman Sachs Group−56.6K (-80%)
- StoneX Group Inc.+39.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LUCD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 24, 2026 | - | Analysis | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 8-K | Mar 26, 2026 | - | - | - |
| 10-K | Mar 25, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
LUCD SEC filings: frequently asked questions
Which institutions hold LUCD stock?
As of September 30, 2026, the largest Lucid Diagnostics Inc. (LUCD) holders among the 13F filers tracked by SignalX were BlackRock ($6.3 million), Vanguard Capital Management LLC ($4.5 million), Wells Fargo & Co ($1.9 million), State Street Corp ($1.8 million), Northern Trust ($929,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LUCD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Lucid Diagnostics Inc. (LUCD) reported revenue of $4.7 million (up 8.3% from FY2024) and a net loss of $58.0 million. Diluted EPS was -$0.69. The figures come from the XBRL data in the 10-K.
What did LUCD report in its latest 8-K?
Lucid Diagnostics Inc. (LUCD) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Lucid Diagnostics announced fiscal quarter results for the period ended September 30, 2026.
What are the latest LUCD SEC filings?
Lucid Diagnostics Inc. (LUCD) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on February 24, 2026.
What is LUCD's SEC CIK number?
Lucid Diagnostics Inc. (LUCD)'s SEC Central Index Key (CIK) is 1799011. EDGAR lists every LUCD filing under that number.
Ask anything about LUCD
The research agent reads LUCD's filings, financials, insider trades and 13F holders, then answers with sources.